G
Greenwich LifeSciences D
D
GLSI
10.920
USD
0.25
(2.34%)
مغلق
حجم التداول
580
الربح لكل سهم
-1
العائد الربحي
-
P/E
-8
حجم السوق
148,842,406
الأخبار المقالات
العنوان: Greenwich LifeSciences
القطاع: Healthcare
الصناعة: Biotechnology
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.